As of 06 Nov 2026 05:10 UTC. Status is always as stated in the latest recorded notice; the sources do not publish resolution, so nothing on this page says a medicine is back — see methodology.
Presentations, as stated in the latest recorded notice
Each line is re-expressed from MSN/2024/031 (18 Mar 2024): the product named, the status the source stated, and the expected-back phrase kept as written. Not the source's sentence, and not an observation of stock.
| Presentation | Status, as stated | Expected back, as stated | Stated in |
|---|---|---|---|
| Semaglutide (Ozempic®) 0.25mg and 1mg solution for injection in a pre-filled pennamed by the source as remaining available · inferred from phrasing · its own page → | Stated as available | — not stated for this line | notice of 18 Mar 2024 |
| Semaglutide (Ozempic®) 0.5mg solution for injection in a pre-filled penaffected product · inferred from phrasing · its own page → | Out of stock, as stated | early June 2024precision: early in the month · window end 10 Jun 2024, derived from “early June 2024” | notice of 18 Mar 2024 |
| Semaglutide (Rybelsus®) 3mg, 7mg and 14mg tabletsnamed by the source as remaining available · inferred from phrasing · its own page → | Stated as available | — not stated for this line | notice of 18 Mar 2024 |
| Dulaglutide (Trulicity®) 0.75mg, 1.5mg, 3mg and 4.5mg solution for injection in a pre-filled pennamed by the source as remaining available · inferred from phrasing · its own page → | Stated as available | — not stated for this line | notice of 18 Mar 2024 |
| Liraglutide (Victoza®) 6mg/ml solution for injection in a pre-filled penaffected product · inferred from phrasing | Out of stock, as stated | — not stated for this line | notice of 18 Mar 2024 |
| Exenatide (Bydureon BCise®) 2mg/0.85ml prolonged-release pre-filled pensnamed by the source as remaining available · inferred from phrasing · its own page → | Stated as available; cannot support an uplift in demand | — not stated for this line | notice of 18 Mar 2024 |
| Exenatide (Byetta®) 5micrograms/0.02ml and 10micrograms/0.04ml pre-filled pensaffected product · inferred from phrasing · its own page → | Discontinued, as stated | — not stated for this line | notice of 18 Mar 2024 |
Protocol in force
No Serious Shortage Protocol matched to this name is in force on the NHSBSA register. Matching is by name until identifier coding lands.
Named in the source as remaining available
- Semaglutide (Ozempic®) 0.25mg and 1mg solution for injection in a pre-filled pen — named by the source as remaining available (inferred from phrasing)
- Semaglutide (Rybelsus®) 3mg, 7mg and 14mg tablets — named by the source as remaining available (inferred from phrasing)
- Dulaglutide (Trulicity®) 0.75mg, 1.5mg, 3mg and 4.5mg solution for injection in a pre-filled pen — named by the source as remaining available (inferred from phrasing)
- Exenatide (Bydureon BCise®) 2mg/0.85ml prolonged-release pre-filled pens — named by the source as remaining available (inferred from phrasing)
Only names the source itself listed, as it listed them (source post ↗). No substitution, dosing or counselling advice is given here or implied.
Identifiers — Glp-1 Ra Products
Grouping under review The name on this page has not been matched to one BNF chemical with enough confidence to assert it; nothing here is grouped until a reviewer confirms it.
BNF chemical and SNOMED identifiers from NHSBSA Prescription Cost Analysis (Open Government Licence), matched by name, confidence not asserted — grouping under review where marked
BNF SNOMED mapping, NHSBSA Copyright 2026; Prescription Cost Analysis (PCA) Monthly Administrative Data, NHSBSA Copyright 2026. This information is licenced under the terms of the Open Government Licence.
History
One supply notification on record, 18 Mar 2024. We record when a shortage is declared, not when stock returns — the source doesn't publish that. An update sharing a reference counts as one episode.
| Issued | Notice | Kind | Tier | Reference |
|---|---|---|---|---|
| 18 Mar 2024 | Medicine Supply Notification: Supply issues with multiple GLP-1 RA products | Supply notification | Tier 3 | MSN/2024/031 |
Also recorded under
No other name appears in this medicine's notice titles. Grouping is by the head name in each title; brand and generic names may still sit on separate pages until identifier coding refines it — see the A–Z.
Scotland — separate record
No NHS Scotland Medicine Supply Alert Notice on record matches this name. Scotland is a separate record (all Scotland alerts); absence here is not a statement about supply in Scotland.